Disease Indications Articles
The World Health Organization has published its first guideline for Ebola virus disease therapeutics, with new strong recommendations for the use of two monoclonal antibodies.
In a Phase II trial of participants with hepatic disease associated with congenital alpha1-antitrypsin deficiency, subcutaneous administration of fazirsitran, an investigational RNA interference therapeutic, reduced both serum and hepatic levels of the mutant hepatotoxic AAT protein Z-AAT, with concurrent improvements in enzymatic and histological markers of liver function.
Subcutaneous administration of marstacimab, an investigational human monoclonal antibody targeting tissue factor pathway inhibitor, resulted in a roughly 10-fold lower annualized bleeding rate in 26 hemophilia patients than comparable control individuals in previous clinical trials who were treated on-demand with recombinant factor replacement therapy.
Sanofi's fitusiran significantly reduced bleeding in a Phase III multinational study in adults and adolescents with hemophilia A or B, with or without inhibitors.
A new study shows treatment with IVIG shows promise for children and young adults with Down syndrome regression disorder (DSRD).
According to CDC, this season’s influenza (flu) vaccines offered meager protection against mild cases of influenza.
FDA has granted breakthrough device designation to Roche’s Elecsys Amyloid Plasma Panel, a new solution to enable Alzheimer’s disease to be detected earlier.
Kedrion Biopharma has created the free, easy-to-use KEDRAB Dose Calculator to help healthcare providers treat rabies exposures.
A previously unknown autoimmune muscle disease involving sudden onset of debilitating muscle pain and weakness has been identified by researchers at Washington University School of Medicine in St. Louis, Mo.
